News, Features, Stories & Reports
Get the latest updates from Neuroblastoma UK, including fundraising stories, research news and charity events.
Sign up to our regular emails for all the updates.
The trial is sponsored and centrally coordinated by Institute Gustave Roussy in Paris and is currently open to recruitment in 17 countries. The trial is open and recruiting in 20 of 21 UK children’s oncology centres apart from one.
Join us at the Good Food Show Summer from 18-21 June at the NEC Birmingham! With live cooking demos, celebrity chefs including James Martin, seasonal flavours, fantastic foodie shopping and more, it’s a great day out for friends and family.
The House of Lords has given its final approval to the Rare Cancers Bill, meaning it can now become law. Jonathan Anderson, Tilly’s Dad, shares why this Bill is so important to him and the Neuroblastoma Community.
Neuroblastoma UK has awarded three Innovation Grants, formally known as Small Grants, in 2025 and late 2024 to support fresh, early-stage research that could pave the way for better treatments for children with neuroblastoma.
In 2013, Neuroblastoma UK joined forces with several other charities to fund the UK component of a unique international study into Opsoclonus Myoclonus Syndrome (OMS). This study was called the UK Multicentre Study of Children with Opsoclonus Myoclonus Syndrome (UMSCOM).
Neuroblastoma UK Patron Alan Carr has won the hit BBC One show The Celebrity Traitors, produced by Studio Lambert. While bluffing, scheming, and deception may be the name of the game, one thing is certain: Alan remains truly faithful to Neuroblastoma UK.
On Friday 3rd October 2025, the Hall Grove School community came together for an evening of laughter and generosity - all in support of Neuroblastoma UK.
As part of Neuroblastoma UK’s 2024 Grant Round, Dr. Olga Piskareva, alongside an international team of researchers received £208,887 to conduct research into the mRNA vaccine.
As part of Neuroblastoma UK’s 2024 Grant Round, Professor Steve Archibald and his team at King’s College London received £268,301 to conduct research into improving the availability of scanning drugs to optimise radiation dose administered in children with neuroblastoma.
In 2021, Neuroblastoma UK awarded £469,093 in research funding to an international team of leading clinician-scientists to explore how blood tests (biomarker testing) could be used in clinical trials to improve outcomes for children with neuroblastoma.
The Rare Cancers Bill, led by Scott Arthur MP, has today passed its Third Reading in the House of Commons, bringing renewed hope to those affected by rare and less common cancers, including devastating childhood cancers such as neuroblastoma.
We need your help to ensure the Rare Cancers Bill passes its third reading.
After months of cross-party support and progress, the Rare Cancers Bill is now at serious risk of falling. We urgently need your help to make sure it passes.
We've been truly inspired by our runners this year, especially with five incredible individuals representing Team Neuroblastoma UK in the TCS London Marathon.
As the 2025 marathon draws nearer, we caught up with two of our runners to hear about the daily routines that keep them motivated, the inspirations behind their journey, and ultimately - what drives them to run for our cause.
April is Teenage and Young Adult Cancer Awareness Month (TYACAM) – an opportunity for
charities and the young people we support to come together and raise awareness of the unique
set of challenges facing this age group after being told they have cancer.
We are honored to announce that Neuroblastoma UK will be featured on the BBC Lifeline Appeal on Sunday, 26 January, at 13.50 on BBC One.
Pupils at Ranby House School in Retford, Nottinghamshire, have released an original song ‘Our Special Story’, in a bid to raise funds for Neuroblastoma UK.
We’re excited to share the launch of a brand-new tool for those navigating treatment pathways for high-risk neuroblastoma. The Redmapp Website is designed to support families facing the difficult decisions that come when their child is faced with uncertainty associated with more complex cases of neuroblastoma.
Researchers from the University of Sheffield and St. Anna Children’s Cancer Research Institute have created a model designed to investigate the origins of neuroblastoma, a cancer primarily affecting infants and young children. The findings offer hope for the creation of tailored treatments which treat aggressive neuroblastomas and minimise the adverse effects experienced by patients from existing therapies.
New research published by Professor Suzanne Turner and led by Dr Perla Pucci in her group at the University of Cambridge Department of Pathology and CRUK Cambridge Centre Paediatric Cancer Programme, has suggested a new target for combination treatment of neuroblastoma and other cancers alongside ALK tyrosine kinase inhibitors (ALK TKI). Resistance to ALK TKI is a challenge and so additional targets for treatments that can be used in combination with ALK TKI are urgently needed.
In 2019, Neuroblastoma UK joined forces with childhood cancer charities The Bradley Lowery Foundation and Niamh's Next Step to support more vital research into neuroblastoma.
A big thank you to Aurora, one of the UK’s fastest-growing Print Management, Office Supplies and Telecoms Providers, for choosing Neuroblastoma UK as one of its charity partners for this year.
This April marks the second Teenage and Young Adult Cancer Awareness Month, an opportunity for charities and the young people we support to come together and raise awareness of the unique challenges facing this age group when faced with the three words that change their lives: “you have cancer”.
It was sold out two months in advance, so it was no surprise to see a packed auditorium at Selwyn College Cambridge for the 6th Neuroblastoma UK Research Symposium on 21st and 22nd March 2024. Over 130 scientists and clinicians attended from across Europe, US, and further afield, including world leading experts in pre-clinical and clinical neuroblastoma research.
In 2023, Dr Gao, working with Prof Juliet Gray and Dr Zoë Walters at the University of Southampton, aimed to determine the role of natural killer cell- mediated anti-tumour effects in neuroblastoma, after treatment with EZH2. The objectives of the study were to look at the correlation between EZH2 protein expression and the surface expression of natural killer ligands in neuroblastoma cells, and to determine if the natural killer cells induced cytotoxicity that could be enhanced in the neuroblastoma cell lines with EZH2 inhibitors.
Neuroblastoma UK (NBUK) and Solving Kids’ Cancer UK (SKCUK) have entered into a formal collaboration to speed up the development of new, better treatments for children with neuroblastoma and bring forward the day when no child dies from or because of the disease.
We know that the start of a New Year can be challenging, especially for those who have lost loved ones. At Neuroblastoma UK, we are sending our kindest thoughts to anyone struggling. Thank you so much for your ongoing support which allows us to not only connect with you, but also to continue funding research into new, more effective and less punishing treatments for children with neuroblastoma.
Thank you for supporting Neuroblastoma UK in 2023.
As we draw closer to the end of a busy but exciting year, all of us at Neuroblastoma UK would like to thank you for your support in the fight against childhood cancer. Here are some of our highlights from the year.
Neuroblastoma UK is awarding £1.1 million in its 2024 grant round to fund new innovative research into neuroblastoma. New therapeutic approaches, pathways to improve existing treatments and exploration of an MRNA vaccine are just some of the projects to be funded in the 2024 grant round; with an emphasis on translational research which can be rapidly transferred from the lab bench to bedside.